In this podcast series, Dr. Jenny Seligmann (University of Leeds, UK), Dr. Autumn McRee (University of North Carolina, USA) and Dr. Dominik Modest (Charité University of Medicine, Germany) discuss the different therapeutic options available in colorectal and gastric cancer.
In this first episode the experts discuss novel targeted approaches in metastatic colorectal and gastric cancer. They discuss practice changing drug targets including BRAF and HER2 with reference to data from recent clinical trials such as DESTINY and HERACLES. They also discuss molecular testing and differences in approaches between the USA and Europe and review recommendations in the guidelines for colorectal and gastric cancer.
What are the common pre-analytical phase challenges in prostate cancer, and how can we overcome them? Why is it important to identify genetic alterations?...
In this podcast, the experts give an overview of the EMERALD trial and present elacestrant as the first, and currently only, oral SERD to...
COR2ED Medical Education: Joanne Chien, Nurse Practitioner specialising in urologic cancers at Stanford Health Care in Palo Alto, California, and Dr Alexander Wyatt, Assistant...